KIDRON NADAV 4
4 · ORAMED PHARMACEUTICALS INC. · Filed Mar 31, 2026
Research Summary
AI-generated summary of this filing
Oramed (ORMP) CEO Nadav Kidron Sells 44,818 Shares for Tax Withholding
What Happened
Nadav Kidron, President, CEO and a director of Oramed Pharmaceuticals (ORMP), disposed of 44,818 shares on 2026-03-30 to satisfy tax withholding obligations related to vested Restricted Stock Units (RSUs). The shares were valued at $3.31 per share, for a total of roughly $148,348.
Key Details
- Transaction date: 2026-03-30; filing date (Form 4): 2026-03-31 (filed within required reporting window).
- Disposed shares: 44,818 at $3.31 per share; total value ≈ $148,348.
- Transaction code: F — shares used to satisfy tax withholding on RSU vesting.
- Footnote: The $3.31/share value equals the issuer’s closing price on the day before vesting.
- Shares owned after transaction: Not disclosed in the supplied filing.
Context
This was a routine stock surrender to cover tax liabilities from RSU vesting (a common corporate practice) rather than an open-market sale that signals a change in investment view. Such tax-withholding dispositions are generally considered administrative and do not necessarily reflect the insider’s sentiment about the company.
Insider Transaction Report
- Tax Payment
Common Stock
[F1]2026-03-30$3.31/sh−44,818$148,348→ 3,422,243 total
- 126,000(indirect: By wholly-owned corporation)
Common Stock
Footnotes (1)
- [F1]Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.